Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 12

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 12
---
 ordinary shares.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Offering price per ordinary share                     |     | $2.612 per share.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Ordinary shares to be outstanding after this offering |     | 84,490,691 ordinary shares.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Use of proceeds                                       |     | We expect to receive net proceeds from this offering of approximately $36.7 million, after deducting offering expenses payable by us.                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                       |     | We intend to use the net proceeds from this offering for general corporate purposes, including research and development related purposes in connection with our product candidates and for potential commercialization of our product candidates. See “Use of Proceeds.”                                                                                                                                                                                                                                                                 |
| Dividend policy                                       |     | We have never declared or paid any cash dividend on our ordinary shares. We currently intend to retain any future earnings and do not expect to pay any dividends in the foreseeable future. Any further determination to pay dividends on our ordinary shares would be at the discretion of our board of directors, subject to applicable laws, and would depend on our financial condition, results of operations, capital requirements, general business conditions, and other factors that our board of directors may deem relevant. |
| Risk factors                                          |     | See “Risk Factors” and the other information included in this prospectus supplement, the accompanying prospectus and under similar headings in the documents that are incorporated by reference into this prospectus supplement or the accompanying prospectus for a discussion of factors you should consider before deciding to invest in our ordinary shares.                                                                                                                                                                         |
| Nasdaq trading symbols                                |     | “DRTS” AND “DRTSW”.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

The number of ordinary shares that will be outstanding immediately after this offering as shown above is based on 70,380,570 ordinary shares issued and outstanding as of December 31, 2024. The number of shares issued and outstanding as of December 31, 2024 as used throughout this prospectus supplement, unless otherwise indicated, excludes:

| ● | 5,391,284 ordinary shares issuable upon the exercise of options outstanding as of December 31, 2024 under 
 our 2016 Share Incentive Plan at a weighted-average exercise price of $5.00 per share;                    |

| ● | 9,058,366 ordinary shares issuable upon the exercise of options outstanding as of December 31, 2024 under 
 our 2021 Share Incentive Plan at a